Bulgaria wants pharmaceutical policies to remain within the member states’ competence, a position which risks undermining the ...

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Detailed price information for Teladoc Health Inc (TDOC-N) from The Globe and Mail including charting and trades.

Net prices that health plans paid for medicines rose a modest 0.4% in the fourth quarter, but that compared unfavorably with a 3% decline in the same period a year earlier.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, ...

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

The U.S. occupies such a central role in the global financial and economic system that if a recession were to happen, it ...

The growing prevalence of ultrahigh-cost drugs under development is prompting health systems nationwide to rethink strategies ...

America’s healthcare system is already a mess -- bloated, bureaucratic, and built for just about everyone except the patients ...